Streetbeat News

Price Targets

MIRM

Cantor Fitzgerald analyst Joshua Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $50 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:10 pm

CABA

Cantor Fitzgerald analyst Joshua Schimmer has maintained an Overweight rating on Cabaletta Bio (NASDAQ:CABA) and increased the price target from $40 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:01 pm

TSHA

Taysha Gene Therapies (NASDAQ:TSHA) received 4 analyst ratings in the last quarter, with 3 being bullish and 1 somewhat bullish. The average 12-month price target is $5.75, with a high of $7.00 and a low of $5.00. This target has decreased by 9.16% from the previous average of $6.33. Analysts use various methods to rate stocks, typically updating their ratings quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

BJRI

BJ's Restaurants (NASDAQ:BJRI) has received mixed analyst ratings in the last quarter, with an average 12-month price target of $32.75, a decrease from the previous target of $35.00. The ratings include 1 bullish, 4 somewhat bullish, 2 indifferent, and 1 somewhat bearish rating. No bearish ratings were reported. The high price target is $43.00 and the low is $23.00.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

UWMC

Analysts have provided mixed ratings for UWM Holdings Corporation (NYSE:UWMC) in the last quarter, with an average price target of $5.38, which is below the current price of $5.76. The average price target has decreased by 2.18% from the previous target of $5.50. The ratings include 1 bullish, 2 indifferent, and 1 somewhat bearish rating over the past three months.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

BTAI

Over the past 3 months, 8 Wall Street analysts have provided ratings for BioXcel Therapeutics (NASDAQ:BTAI), with 7 bullish and 1 indifferent. The average 12-month price target is $10.12, representing an 83.13% decrease from the previous target of $60.00. Analysts predict stock performance based on company financials, meetings, and insider communications, typically updating their ratings quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

SOFI

Analysts have provided mixed ratings for SoFi Technologies, Inc. (NASDAQ:SOFI) with 1 bullish and 5 indifferent ratings in the last quarter. The average 12-month price target among 6 analysts is $9.25, with a high of $14.00 and a low of $7.00. This target is a 13.31% decrease from the previous target of $10.67. Analyst ratings are opinions on stock performance and are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

TCBI

Texas Capital Bancshares (NASDAQ:TCBI) has received 5 analyst ratings in the last quarter, with 4 being bullish and 1 indifferent. The 12-month price targets for TCBI suggest an average target of $67.6, a decrease from the previous $70.80 target. Analysts use various data sources to provide these ratings, which are opinions and not guarantees of performance.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:00 pm

TSHA

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and increased the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:59 pm

SMTI

Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on Sanara MedTech (NASDAQ:SMTI) but reduced the price target from $59 to $49.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:56 pm